CareDx's (CDNA) Neutral Rating Reiterated at HC Wainwright

CareDx (NASDAQ:CDNA - Get Free Report)'s stock had its "neutral" rating reiterated by stock analysts at HC Wainwright in a report released on Tuesday, Benzinga reports.

Several other equities research analysts have also commented on CDNA. The Goldman Sachs Group increased their price objective on shares of CareDx from $26.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, October 16th. BTIG Research upgraded shares of CareDx from a "neutral" rating to a "buy" rating and set a $40.00 price objective for the company in a research note on Monday, August 19th. StockNews.com upgraded shares of CareDx from a "hold" rating to a "buy" rating in a research note on Thursday, October 17th. Craig Hallum raised their price target on shares of CareDx from $22.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, August 1st. Finally, Wells Fargo & Company assumed coverage on shares of CareDx in a research note on Tuesday, August 27th. They set an "underweight" rating and a $28.00 price target for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, CareDx presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.60.

CareDx Price Performance

Shares of CDNA stock traded down $0.33 on Tuesday, reaching $23.14. 672,088 shares of the company were exchanged, compared to its average volume of 909,200. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -6.77 and a beta of 1.77. The company has a 50-day moving average of $29.46 and a 200-day moving average of $19.97. CareDx has a one year low of $4.80 and a one year high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.37. CareDx had a negative net margin of 53.73% and a negative return on equity of 53.65%. The company had revenue of $92.27 million for the quarter, compared to analyst estimates of $67.20 million. As a group, sell-side analysts predict that CareDx will post -0.84 EPS for the current year.

Insider Buying and Selling

In other news, Director Peter Maag sold 35,552 shares of the company's stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $33.04, for a total value of $1,174,638.08. Following the transaction, the director now owns 330,024 shares in the company, valued at approximately $10,903,992.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other CareDx news, insider Alexander L. Johnson sold 21,557 shares of the company's stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total transaction of $702,327.06. Following the completion of the sale, the insider now directly owns 284,983 shares of the company's stock, valued at approximately $9,284,746.14. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter Maag sold 35,552 shares of the company's stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $33.04, for a total transaction of $1,174,638.08. Following the sale, the director now directly owns 330,024 shares of the company's stock, valued at approximately $10,903,992.96. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 91,340 shares of company stock valued at $3,025,415 over the last quarter. Corporate insiders own 4.20% of the company's stock.

Institutional Trading of CareDx

Hedge funds and other institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC grew its stake in shares of CareDx by 10,267.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 18,661 shares of the company's stock worth $198,000 after buying an additional 18,481 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of CareDx by 87.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 228,198 shares of the company's stock worth $2,417,000 after buying an additional 106,660 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of CareDx in the 1st quarter worth $238,000. Russell Investments Group Ltd. grew its stake in shares of CareDx by 35.0% in the 1st quarter. Russell Investments Group Ltd. now owns 122,227 shares of the company's stock worth $1,294,000 after buying an additional 31,667 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of CareDx by 4.4% in the 1st quarter. Vanguard Group Inc. now owns 4,300,016 shares of the company's stock worth $45,537,000 after buying an additional 180,334 shares in the last quarter.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.